Tag: Taxotere
Articles
- Latest research concerning side effects of chemotherapy
- Latest research concerning triple negative breast cancer prognosis
- Latest research on factors influencing Taxol (paclitaxel) effectiveness
- What should breast cancer patients eat during Taxol (paclitaxel) chemotherapy?
News
- A story of long-term stage IV HER2+ breast cancer survival
- Bisphosphonates for treating osteoporosis may significantly reduce risk of breast cancer
- Brassica compound DIM inhibits breast cancer cell growth synergistically with Taxotere
- Fish oil component can increase survival time for Stage IV breast cancer patients
- Garlic compound prevents cell progression to breast cancer
- Muscle and joint pain are common during taxane chemotherapy for breast cancer
- Neutropenia during chemotherapy predicts favorable breast cancer outcome
- Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer
- Possible toxic side effects of chemotherapy
- Resveratrol increases effectiveness of Taxotere (docetaxel) and Adriamycin (doxorubicin)
- Resveratrol increases the effectiveness of Taxol in triple negative cells
- Survival times for metastatic breast cancer have been improving
Foods
Studies
- 3, 3'-diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through down-regulation of FoxM1
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity
- Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo
- d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis
- Differential response from neoadjuvant chemotherapy across breast cancer subtypes
- Exogenous supplementation with [omega]-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells
- Fifteen-year trends in metastatic breast cancer survival in Greece
- Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer
- Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide
- Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice
- Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
- Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel
- Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
- Muscle and Joint Symptoms in Breast Cancer Patients Receiving Taxane-Based Chemotherapy
- Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in northeast china
- Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer
- Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro
- Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane
- Surgery for widely disseminated breast cancer: prolonged control by excision of metastases